AstraZeneca PLC (AZN)'s Brilique is First Drug to Gain Post-AMNOG Decision in Germany
12/19/2011 8:44:14 AM
Germany's Federal Joint Committee (G-BA) has delivered a positive opinion for AstraZeneca's antiplatelet therapy Brilique, the first drug to be assessed under new pricing assessment laws that came into effect on January 1, 2011. Overall, the G-BA came down in favour of Brilique (ticagrelor) as a treatment for patients with acute coronary syndromes, allowing AstraZeneca to start pricing negotiations with the German health insurance system in the New Year. "The G-BA's final assessment acknowledges the additional benefit that Brilique provides approximately 80 per cent of the ACS patient population in Germany," said AstraZeneca in a statement.